XTalks

FEBRUARY 5, 2025

a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 If successful, Phase III trials are expected to follow shortly thereafter.

Hormones 59

Hormones Bioavailability Clinical Trials Clinical Trials 59

pharmaphorum

JULY 22, 2021

The deal focuses on ARV-471, currently in phase 2 testing for advanced breast cancer patients whose tumours expresses oestrogen receptors – so are hormone sensitive – but test negative for HER2 receptors that would make them candidates for treatment with drugs like trastuzumab. billion in backloaded milestone payments.

Protein 116

Protein Hormones Bioavailability Drugs 116

XTalks

FEBRUARY 3, 2023

Aditya Bardia, MD, MPH, director of Breast Cancer Research at Mass General Cancer Center, associate professor at the Medicine Department at Harvard Medical School and principal investigator for the EMERALD trial, in the same press release statement. Mutations in the ESR1 , however, have contributed to the rise of endocrine resistance.

Clinical Trials 97

Clinical Trials Clinical Trials FDA Approval Trials 97

XTalks

OCTOBER 2, 2024

If successful, this trial could pave the way for a New Drug Application (NDA) submission. With positive outcomes in preclinical models, EB-003 has confirmed oral bioavailability, adding to its therapeutic potential. This development highlights a growing interest in neuroplastogens as alternative mental health treatments.

Research 52

Research Bioavailability Trials Hormones 52

Delveinsight

JULY 30, 2020

The buildup in adrenal glands leads to the insufficient hormonal response, thus leading to several of the symptoms such as deficiency of steroid hormones (mainly cortisol and aldosterone), impaired cortisol secretion, and others that are harbingers of the disease. A novel, brain penetrant, orally bioavailable and selective PPAR?

Hormones 52

Hormones Marketing Gene Trials 52

Delveinsight

JANUARY 7, 2021

The immunotherapy pipeline is led by an in-licensed EP4 antagonist that Ikena is testing combined with Keytruda in phase 1b/2 colorectal and non-small cell lung cancer clinical trials. Eli Lilly backed Terns Pharmaceuticals now has two NASH candidates in clinical trials. IND-enabling studies are underway.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52